Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROH-201 Ophthalmic Solution Phase 2a Trial in Dry Eye Disease
jRCT2051200158Phase 2Completed
- Sponsor
- Rohto Pharmaceutical Co., Ltd.
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in dry eye syndrome (DED) comparing ROH-201 ophthalmic solution with Placebo (2 arms). Primary endpoint: Change from baseline in fluorescein staining score. Started Mar 2021; status: completed.
02
Drugs
delgocitinib
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on jRCT2051200158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051200158.